Docket No.: B45331

DECLARATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject marter which is claimed and for which a patent is sought on the invention entitled:

"HPV-16 AND -18 L1 VLP VACCINE"

the specification of which (check one)
[] is attached hereto.

[X] was filed on 18 December 2003 and was amended on

as Seria: No. PCT/EP2003/014562 (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number Countr

Filing Date

Priority Claimed

I hereby claim the benefit under Title 35, United States Code. Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
60/435035	20 December 2002
60/496653	20 August 2003

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is rot disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.

Filing Date

Status

Direct all correspondence to the address associated with Customer Number 20462.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wil ful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor:

Gary DUBIN

Inventor's	Signature:
Inventor s	DIBHALUIC.

Date: June 24, 2005

Residence:

King of Prussia, Pennsylvania, United State: of America

Citizenship:

US

Post Office Address: GlaxoSmithKline

Corporate Intellectual Property - UW: 220

P.O. Box 1539

King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Bruce INNIS

Inventor's Signature:

June 24, 2005

Residence:

King of Prussia, Pennsylvania, United States of America

Citizenship:

US

Post Office Address: GlaxoSmithKline

Corporate Intellectual Property - UW:2220

P.O. Box 1539

King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Moncef Mohammed SLAOUI

Inventor's Signature:

Date:

Residence:

King of Prussia, Pennsylvania, United States of America

Citizenship:

BE

Post Office Address: GlaxoSmithKline

Corporate Intellectual Property - UW 220

P.O. Box 1539

King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Martine Anne Cecile WETTENDOPFF

Inventor's Signature:

aust 22, 2005

Residence:

Rixensart, Belgium

Citizenship:

BE

Post Office Address: GlaxoSmithKline

Corporate Intellectual Property - UW2:20

P.O. Box 1539

King of Prussia, Pennsylvania 19406-0939